KZR — Kezar Life Sciences Share News
0.000.00%
Last trade - 00:00US FDA puts Kezar Life Sciences' lupus treatment trial on hold after patient deaths (updated)
Brief: Kezar Life Sciences Announces Clinical Hold Of Zetomipzomib Ind For Treatment Of Lupus Nephritis
US FDA puts clinical hold on Kezar Life Sciences' lupus treatment trial
U.S. RESEARCH ROUNDUP- Amerant Bancorp, BlackRock, Equinix
Kezar Life Sciences halts mid-stage trial for lupus treatment (updated)
Brief: Kezar Life Sciences Ceases Enrollment, Dosing In Mid-Stage Trial Of Zetomipzomib
Kezar Life Sciences halts mid-stage trial for lupus treatment
Kezar Life Sciences Inc expected to post a loss of 32 cents a share - Earnings Preview
Brief: Kezar Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)
Brief: Kezar Notified By Nasdaq In Letter Dated May 31, Co's Application To Transfer To Nasdaq Capital Market Was Approved
Brief: Kezar Life Sciences Q1 Net Income USD -21.658 Million
Kezar Life Sciences Inc expected to post a loss of 33 cents a share - Earnings Preview
Brief: Kezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(C)(4)
Brief: Kezar Life Sciences Registering Offer And Sale Of Shares Of Common Stock Of Up To $24.8 Million From Time To Time Through TD Cowen
Kezar Life Sciences Inc reports results for the quarter ended in December - Earnings Summary
Brief: Kezar Life Sciences Q4 Operating Income USD -34.589 Million
Kezar Life Sciences Inc expected to post a loss of 38 cents a share - Earnings Preview
Brief: Everest Medicines And Kezar Life Sciences Receive IND Approval From China NMPA For Palizade Trial In Lupus Nephritis
U.S. RESEARCH ROUNDUP-Beauty Health, Design Therapeutics, Energizer Holdings